Alzheimer's prevention initiative adad colombia trial program
Active Project Grant Awarded Last action
- Award ID
- R01AG086363
- Recipient
-
Banner Health UEI SB35ENJFKK14
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $62,157,104
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 44% complete
- Place of performance
- Phoenix, AZ 85012, USA
Award details come from USAspending.gov.
Description
- Abstract
- When the API autosomal dominant alzheimer's disease (ADAD) colombia trial (NCT01998841) was announced in 2012, IT launched a new ERA in ad prevention research. The trial led US to identify ~6,000 persons from the world's largest ADAD kindred, including nearly 1,200 presenilin 1 (PSEN1) E280A mutation carriers, who are virtually certain to develop ad and become cognitively impaired at 44 (SD ± 5) years of age; establish the clinical trials, infusion capability, pet, and MRI infrastructure colombia needed to conduct interventional studies in the kindred; and introduce precedent setting scientific, ethical, social support, and logistical paradigms as well as pioneering sample sharing agreements. Moreover, IT demonstrated the ability to evaluate an experimental treatment in a vulnerable population from a developing country in ways that the participants valued, such that 94% of participants completed the 5-8 year trial. In recent landmark pivotal trials, the AΒ plaque-clearing antibody (PCA) treatments lecanemab and donanemab were associated with a significant clinical benefit in mildly impaired late-onset ad (LOAD) patients, with dramatic AΒ pet and plasma ptau reductions, and significant effects on other AΒ, TAU, neurodegenerative, and inflammatory (a/T/N/I) biomarkers. These data provided compelling support for the role of AΒ aggregates in the development, treatment, and prevention of ad and support the use of biomarker endpoints that are likely to be associated with a clinical benefit. Here, we propose to conduct a two-part clinical trial in 200 cognitively unimpaired and mildly impaired PSEN1 mutation carriers and 40 placebo-treated non-carriers from this remarkable kindred. In part 1, carriers will receive up to 18 months of a plaque-clearing antibody (PCA) treatment (exemplar: donanemab), permitting US to compare the magnitude of AΒ pet and plasma ptau reductions in this ADAD kindred to that observed in trials of the same drug in AΒ+ mildly impaired LOAD patients and cognitively unimpaired older adults. In part 2, carriers will be randomized to receive 1) continued PCA treatment, 2) an oral gamma secretase modulator (GSM) treatment (exemplar: RG6289) with the potential to minimize the RE-accumulation of AΒ aggregates in a complementary, potentially less expensive, and more scalable way, 3) combined PCA/GSM treatment, and 4) placebo treatment for 18 months. This seamless, double-blind, placebo-controlled, double-dummy study of a PCA and a GSM in cognitively unimpaired and MCI/mild ad PSEN1 E280A mutation carriers will efficiently address a number of key questions including (1) determining the efficacy of a PCA in reducing brain amyloid levels in ADAD; (2) examining the relative efficacy of combination treatment following PCA treatment versus PCA monotherapy versus GSM monotherapy versus placebo to further lower or maintain low brain amyloid levels as well as on downstream biomarkers; (3) estimating how long placebo-treated mutation carriers remain amyloid negative following PCA- induced amyloid clearance; (4) providing a foundation for understanding the longer term clinical impact of the interventions leveraging the colombian API registry; and (5) providing invaluable data and samples for the field.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $351,021 | |
| Amendment | $20,993,265 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $344,001 | |
| Amendment | $344,001 | |
| Amendment | $15,521,010 | |
| Amendment | $15,521,010 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $4,541,398 | |
| Original award | $4,541,398 |
Show all 15
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Trustees Of Indiana University | $1,793,740 | |
| Trustees Of Boston University | $106,735 | |
| Fundacion Universidad De Antioquia | $936,594 | |
| The General Hospital Corporation | $49,287 |
Quick answers
Who received award R01AG086363?
R01AG086363 was awarded to Banner Health by National Institute on Aging (National Institutes of Health) on September 1, 2024.
How much is award R01AG086363 worth?
$62,157,104 has been obligated on R01AG086363.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award